(OrthoSpineNews)- Kolosis BIO (Kolosis), a leading provider of orthobiologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are proud to announce the extension of their successful partnership. The agreement secures Kolosis BIO’s exclusive rights to market the highly-regarded Kore Fiber and Prime HD bone graft technologies and reinforces the commitment between the organizations to advance patient outcomes and drive industry adoption of superior bone graft technologies.

“We are thrilled to continue our exclusive partnership with MTF Biologics,” said Collin Begley, CEO of Kolosis BIO. “Their proprietary aseptic processing methods and uncompromising commitment to quality align perfectly with our mission to provide patients with the best possible bone grafting options. We look forward to collaborating on new technologies and continuing to make a meaningful impact together in the orthobiologics market.”

“Kolosis BIO’s focus on delivering high-quality bone graft products and expanding their market share make them a valuable partner,” said Brad Bailey, VP & General Manager of Orthopedics at MTF Biologics. “We are excited to continue working together to find new and innovative allograft solutions that will benefit patients and honor the Gift of Donation.”